FindTrial
Sign In

IDE397

DRUG4 trials

Sponsors

Amgen Inc., IDEAYA Biosciences, Amgen

Conditions

Adenocarcinoma of EsophagusBladder CancerGastric AdenocarcinomaGastroesophageal Cancer (GC)In Part 1MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid TumorsMesothelioma

Phase 1

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Active, not recruitingNCT04794699
IDEAYA BiosciencesSolid Tumor
Start: 2021-04-14End: 2027-02-04Updated: 2026-04-09
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
CompletedNCT05975073
AmgenMTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
Start: 2023-08-01End: 2026-03-26Updated: 2026-04-22
A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
CompletedCTIS2023-504364-42-00
Amgen Inc.In Part 1, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer +1
Start: 2024-09-12End: 2025-04-28Target: 12Updated: 2024-07-10
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingNCT07277413
IDEAYA BiosciencesAdenocarcinoma of Esophagus, Bladder Cancer, Gastric Adenocarcinoma +8
Start: 2026-03-04End: 2028-04-30Target: 260Updated: 2026-04-03

Related Papers

Abstract 4268: The allosteric MAT2A inhibitor IDE397 uniquely exploits metabolic liabilities associated with MTAP deletion to perturb DNA replication and repair
Cancer Research2025-04-211 citations
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.
2025-01-0618 citations
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers.
2025-01-0412 citations
Abstract B027: The MAT2A inhibitor IDE397: a novel combination backbone for urothelial cancer subjects with MTAP deficiency
Clinical Cancer Research2024-05-172 citations